TrialBritish journal of clinical pharmacology2015

4β-hydroxycholesterol as an endogenous CYP3A marker in cancer patients treated with taxanes.

Anne-Joy M de Graan et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.